Theriva Biologics Stock Buy Hold or Sell Recommendation
| TOVX Stock | USD 1.28 0.02 1.59% |
Given the investment horizon of 90 days and your highly speculative risk level, our recommendation regarding Theriva Biologics is 'Cautious Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Theriva Biologics given historical horizon and risk tolerance towards Theriva Biologics. When Macroaxis issues a 'buy' or 'sell' recommendation for Theriva Biologics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Theriva Biologics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Theriva Stock please use our How to Invest in Theriva Biologics guide. In addition, we conduct extensive research on individual companies such as Theriva and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Theriva Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Theriva |
Execute Theriva Biologics Buy or Sell Advice
The Theriva recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Theriva Biologics. Macroaxis does not own or have any residual interests in Theriva Biologics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Theriva Biologics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Theriva Biologics Trading Alerts and Improvement Suggestions
| Theriva Biologics generated a negative expected return over the last 90 days | |
| Theriva Biologics has high historical volatility and very poor performance | |
| Theriva Biologics may become a speculative penny stock | |
| Theriva Biologics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (18.35 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Theriva Biologics currently holds about 52.27 M in cash with (19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.3, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Theriva Biologics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from medcitynews.com: Twin Brothers Launch Seen Health with 22M to Provide Culturally-Focused Care for Seniors |
Theriva Biologics Returns Distribution Density
The distribution of Theriva Biologics' historical returns is an attempt to chart the uncertainty of Theriva Biologics' future price movements. The chart of the probability distribution of Theriva Biologics daily returns describes the distribution of returns around its average expected value. We use Theriva Biologics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Theriva Biologics returns is essential to provide solid investment advice for Theriva Biologics.
| Mean Return | -0.57 | Value At Risk | -24.57 | Potential Upside | 34.29 | Standard Deviation | 13.29 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Theriva Biologics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Theriva Biologics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (13.9M) | (8.8M) | 61.1M | (25.4M) | (18.6M) | (17.7M) | |
| Free Cash Flow | (13.9M) | (12.2M) | (12.9M) | (19.2M) | (17.3M) | (18.1M) | |
| Other Non Cash Items | 72K | 178K | 952K | 2.3M | (2.0M) | (1.9M) | |
| Net Income | (15.4M) | (10.1M) | (14.3M) | (19.7M) | (18.3M) | (19.3M) | |
| End Period Cash Flow | 15.0M | 6.2M | 67.3M | 41.9M | 23.3M | 12.9M | |
| Investments | 0.0 | (9K) | (14K) | (4.4M) | (237K) | (248.9K) | |
| Change To Netincome | 335K | 455K | 415K | 1.1M | 1.3M | 1.4M |
Theriva Biologics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Theriva Biologics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Theriva Biologics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Theriva stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.77 | |
β | Beta against Dow Jones | 1.56 | |
σ | Overall volatility | 13.34 | |
Ir | Information ratio | -0.05 |
Theriva Biologics Volatility Alert
Theriva Biologics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Theriva Biologics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Theriva Biologics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Theriva Biologics Fundamentals Vs Peers
Comparing Theriva Biologics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Theriva Biologics' direct or indirect competition across all of the common fundamentals between Theriva Biologics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Theriva Biologics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Theriva Biologics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Theriva Biologics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Theriva Biologics to competition |
| Fundamentals | Theriva Biologics | Peer Average |
| Return On Equity | -0.59 | -0.31 |
| Return On Asset | -0.25 | -0.14 |
| Current Valuation | (11.11 M) | 16.62 B |
| Shares Outstanding | 2.78 M | 571.82 M |
| Shares Owned By Insiders | 10.48 % | 10.09 % |
| Shares Owned By Institutions | 21.20 % | 39.21 % |
| Number Of Shares Shorted | 90.95 K | 4.71 M |
| Price To Book | 0.14 X | 9.51 X |
| EBITDA | (19.85 M) | 3.9 B |
| Net Income | (18.35 M) | 570.98 M |
| Cash And Equivalents | 52.27 M | 2.7 B |
| Cash Per Share | 3.30 X | 5.01 X |
| Total Debt | 2.15 M | 5.32 B |
| Debt To Equity | 0.03 % | 48.70 % |
| Current Ratio | 4.14 X | 2.16 X |
| Book Value Per Share | 53.89 X | 1.93 K |
| Cash Flow From Operations | (19 M) | 971.22 M |
| Short Ratio | 0.03 X | 4.00 X |
| Earnings Per Share | (32.59) X | 3.12 X |
| Target Price | 90.5 | |
| Number Of Employees | 22 | 18.84 K |
| Beta | 1.34 | -0.15 |
| Market Capitalization | 3.56 M | 19.03 B |
| Total Asset | 55.22 M | 29.47 B |
| Retained Earnings | (309.32 M) | 9.33 B |
| Working Capital | 20.66 M | 1.48 B |
| Net Asset | 55.22 M |
Note: Acquisition by Kraws Jeffrey J of 110000 shares of Theriva Biologics subject to Rule 16b-3 [view details]
Theriva Biologics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Theriva . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Theriva Biologics Buy or Sell Advice
When is the right time to buy or sell Theriva Biologics? Buying financial instruments such as Theriva Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Theriva Biologics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run USD Crypto Fund Thematic Idea Now
USD Crypto Fund
Fund from digital currency traded on multiple global exchanges in US dollors. The USD Crypto Fund theme has 24 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize USD Crypto Fund Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Theriva Stock Analysis
When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.